SLC1A2 and glioblastoma: Additionally, treatment with an agonist of the peroxisome proliferator activated receptor gamma (PPARγ), pioglitazone, increased the expression of EAAT2 in human glioblastoma cells and reduced their viability, indirectly confirming the inverse correlation between the level of this transporter and cell survival [82].